Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Decreases By 57.1%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 1,200 shares, a decrease of 57.1% from the January 31st total of 2,800 shares. Based on an average daily trading volume, of 32,600 shares, the days-to-cover ratio is presently 0.0 days.

SAB Biotherapeutics Stock Performance

Shares of SAB Biotherapeutics stock traded up $0.00 on Monday, hitting $0.03. The stock had a trading volume of 1,352 shares, compared to its average volume of 40,286. The stock has a 50 day moving average of $0.07 and a 200 day moving average of $0.05. SAB Biotherapeutics has a twelve month low of $0.01 and a twelve month high of $0.18.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.